Does Losartan Affect Sex Drive? What the Studies Actually Show

If you searched losartan and sex drive, the honest answer is short. Losartan is unlikely to be what flattened you, and the evidence that it helps is weaker than the internet says. The one losartan sexual-function study was open-label with no control group: 82 men over 12 weeks, sexual satisfaction from 7.3% to 58.5%. The randomized trials used valsartan, a sibling drug: 5.8 to 7.4 intercourse episodes a month at P = 0.058, against atenolol at 6.0 to 4.2. A network meta-analysis of 25 trials found no blood-pressure class separated from placebo on erection scores. High blood pressure itself goes with lower function, at odds 2.789 in women.

Figures from Llisterri et al. 2001 (PMID 11370797), Fogari et al. 2004 (PMID 14700518) and Choy et al. 2019 (PMID 31113742). The first is uncontrolled, the second is valsartan and not losartan, the third pools observational studies.

Is it the losartan, or is it me?

You searched a drug name and a symptom, which is what people do at 11pm. Most pages that answer you are selling something. This one reports what the trials support.

Most people on losartan arrived from somewhere else. Blood-pressure lists start with a thiazide-type diuretic, an ACE inhibitor, a calcium channel blocker or an angiotensin receptor blocker, and beta blockers get added for a heart reason, an older prescription, or a side effect you could not stomach. If you came off a beta blocker, that class carries the trial record for erection problems and reduced activity, and those months leave a mark. Our page on beta blockers and sex drive charts the TOMHS trial and the network meta-analysis.

Losartan is an angiotensin receptor blocker, the class reviews call neutral or beneficial for sexual function. Manolis and colleagues (2012), La Torre and colleagues (2015), Corona and colleagues (2025) and Zhong and colleagues (2022) all place it there. The pointing is weak and mostly belongs to valsartan, so this page says so every time it borrows a number.

Desire is not a lab value, so clean labs and feeling flat can coexist: numbers fine, still flat. Statins get blamed in the same threads, and statins and sex drive goes through them.

The one losartan study, and its hole

Llisterri and colleagues (2001) screened 323 hypertensive men and women and kept 82 men aged 30 to 65 with uncontrolled blood pressure at 140/90 mm Hg or higher plus a diagnosed sexual problem. They took losartan at 50 to 100 milligrams a day for 12 weeks, measured with a self-administered questionnaire that had been validated in 60 other subjects with hypertension.

The headline numbers are large. Sexual satisfaction rose from 7.3% at baseline to 58.5% (chi-square; P = 0.001). Men reporting a high frequency of sexual activity went from 40.5% to 62.3%, and the men in the low and very low frequency groups dropped out of those categories (chi-square; P = 0.001). Quality of life improved in 73.7%, showed no change in 25.5%, and felt worse in 0.8%. In men who started with no sexual difficulty, losartan's effect on sexual function was nonsignificant.

Then comes the sentence nobody quotes. At week 12, only 11.8% of the treated subjects reported an improvement in sexual function. The abstract prints that beside 58.5% and leaves them unreconciled. A satisfaction item and a global did-you-improve item can disagree, and with no control arm nothing settles which one moved.

The study had no control group, no placebo and no blinding, and that swallows every percentage above. Blood pressure measured repeatedly drifts down. Men recruited at their worst regress toward their own average. Being watched and asked moves sexual reporting. Lower pressure is itself a change in how a body works. All four push the way the result went.

The other losartan-era signal sits in a pharmacovigilance file. Ekman and colleagues (2010) pulled every erection-problem report filed with the Swedish Medical Products Agency from 1990 to 2006 naming a blood-pressure drug as the suspected agent: 225 reports, 59 on blood-pressure drugs including angiotensin receptor blockers, 9 cases in that group. Positive dechallenge appeared in 43 cases, 72%. Reports have no denominator of users, so those numbers give you no rate, and the paper never names which drug in the class was implicated.

The valsartan trials, which are not losartan

Fogari and colleagues (2002) ran the cleanest test in this whole story. Newly diagnosed, previously untreated men aged 40 to 49, no prior sexual difficulty, matched for marital status: 110 of them, double-blind, on valsartan 80 milligrams daily or atenolol 50 milligrams daily for 16 weeks, dose doubled at 8 weeks if diastolic pressure stayed above 90 mmHg. Atenolol cut activity from 6.0 to 4.2 intercourse episodes a month, and the paper puts that against placebo at P < 0.01. Valsartan raised activity from 5.8 to 7.4 at P = 0.058 against placebo, which clears no threshold, and separated from atenolol (P < 0.05). Testosterone fell on atenolol, 18.2 nmol/l to 13.8 nmol/l (P < 0.01 against baseline), and valsartan left it at 17.6 to 18.3 nmol/l.

The same group asked women. Fogari and colleagues (2004) took 120 sexually active postmenopausal women aged 51 to 55 with diastolic pressure 95 to 105 mm Hg, ran a 4-week placebo period, then gave valsartan 80 milligrams (n = 60) or atenolol 50 milligrams (n = 60) once daily for 16 weeks. A 10-item self-evaluation questionnaire on desire, finishing and sex was scored on a visual analog scale at baseline and week 16. Both drugs lowered pressure alike. On valsartan, desire rose 38% (P < .01), behavior changed 45% (P < .001) and fantasies rose 51% (P < .001). On atenolol, desire fell 18% (P < .01) and fantasies fell 23% (P < .001). The abstract calls that questionnaire self-evaluation and nothing stronger, and no placebo arm ran after run-in.

Fogari and colleagues (2001) screened 160 newly diagnosed hypertensive men aged 40 to 49 and randomized 120 to carvedilol 50 milligrams or valsartan 80 milligrams once daily for 16 weeks, then crossed them over after another placebo period; 40 men took placebo for 16 weeks in a single-blind design. In month one, episodes fell from 8.2 to 4.4 on carvedilol (P < .01). On valsartan they went from 8.3 to 6.6, and the paper labels that change nonsignificant. On continuing, carvedilol slid to 3.7 while valsartan recovered to 10.2, and the crossover confirmed it. Erection complaints came from 15 men on carvedilol (13.5%), one man on valsartan (0.9%) and one man on placebo.

One comparator, because the contrast is the story. Fogari and colleagues (1998) followed 90 hypertensive men aged 40 to 49, all married, no history of sexual difficulty, on atenolol 100 milligrams or lisinopril 20 milligrams for 16 weeks in a crossover design. In month one episodes fell on both: atenolol from 7.8 to 4.5 (P < .01 against placebo), lisinopril from 7.1 to 5.0 (P < .05 against placebo). On continuing, lisinopril drifted back to 7.7 while atenolol sat at 4.2, a gap the paper calls significant (P < .01), and complaints of sexual symptoms ran 17% against 3% (P < .05). Lisinopril is an ACE inhibitor, so read this trial as the comparison arm in the story; it adds nothing about losartan.

What the pooled analyses say

Ismail and colleagues (2019) pooled 4 randomized trials and 2,809 men on angiotensin receptor blockers against conventional therapy or no treatment; three reported adequate random sequence allocation and two reported adequate blinding. Sexual activity improved on the ARB valsartan, mean difference 0.71 (95% CI 0.66 to 0.76, I squared = 0%). Erection scores showed no significant rise with losartan or telmisartan against control or placebo: n = 203 against n = 232, mean difference 1.36, 95% CI -0.97 to -3.69, I squared = 80%. A positive point estimate sitting outside an interval of -0.97 to -3.69 is unstable, and 80% heterogeneity means four trials measuring four different things.

Farmakis and colleagues (2022) ran a network meta-analysis: 25 studies and 7,784 people in the qualitative synthesis, 16 studies quantified. Risk of bias was concerning or high in the majority of studies and inconsistency was high. No significant differences in erection scores appeared between major classes, and with placebo as the reference no treatment strategy, ARBs included, showed a significant effect. Our beta-blocker page cites this analysis, so it stays in prose here.

Choy and colleagues (2019) worked on women. Their search of 3 electronic databases in August 2018 started at 2,198 studies. In the end 31 studies were kept, covering 18,260 subjects. Hypertensive women scored in the dysfunction range at 42.1%, and pooled odds against normotensive women came to 2.789 (95% CI 1.452 to 5.357, P = .002). Treated hypertension against untreated showed no difference (OR = 1.229, 95% CI 0.675 to 2.236, P = .5). The review tested each drug class on its own, angiotensin receptor blockers among them, and none separated on sexual function. Many studies were dropped for unavailable data and the included studies used different tools, so treat that 42.1% as a rough centre of a wide spread.

Thomas and colleagues (2016) used baseline data from women in SPRINT, a trial of people aged 50 and older with hypertension at high cardiovascular risk. Of 690 women in the quality-of-life subset, 183 (26.5%) were sexually active. Activity rates looked the same for women on one or more antihypertensives and women on none. Women taking an ACE inhibitor or an angiotensin receptor blocker had higher odds of being sexually active (odds ratio 1.66, 95% CI 1.12 to 4.27, P = 0.011), a wide interval on baseline data with no before-and-after. Among the sexually active women, 52.5% scored in the dysfunction range and no medication class was associated in the multivariable model.

Wang and colleagues (2025) randomized 130 men with essential hypertension at one Chinese center, open-label, for 6 months: an ARB plus amlodipine against the same ARB plus metoprolol. Total scores improved in the amlodipine arm (p = 0.015), with intercourse satisfaction at p = 0.003 and desire sitting unchanged at p = 0.08. Scores fell in the metoprolol arm (p = 0.008), with desire down at p = 0.003. Blood pressure fell in both arms. The ARB studied is allisartan isoproxil, and the partner drug looks like what moved the scores.

The blood pressure itself

Spatz and colleagues (2013) surveyed 3,005 adults aged 57 to 85 in three groups: treated hypertension, untreated hypertension, none. Among men, activity was least common in the treated group (66.5% against 75.9% and 71.5%, P < 0.01) and problems most common there (69.1% against 57.7% and 54.3%, P ≤ 0.01). In the model, treated hypertension showed no association with activity (OR = 0.86, 95% CI 0.51 to 1.45) and a nonsignificant one with problems (OR = 1.49, 95% CI 0.94 to 2.37). Among women, activity was lower in both hypertension groups (35.2%, 38.3% and 58.0%, P < 0.01), with problems similar across the three groups (73.7%, 65.3%, 71.7%, P = 0.301). No medication class, the ACE inhibitor and ARB group included, showed a significant association. The survey took one snapshot of self-reports, so it shows company and leaves cause open.

Kloner and colleagues (2007) report that recent analyses suggest about 67 to 68% of men with hypertension have some degree of erection problems, more severe than in the general population, and name thiazide diuretic and beta-blocker therapy as contributors. The abstract gives no design behind that prevalence figure.

TOMHS gives the cleanest table with no ARB in it. Grimm and colleagues (1997) followed 902 people aged 45 to 69 with stage I diastolic hypertension on placebo or one of five drugs (acebutolol, amlodipine, chlorthalidone, doxazosin and enalapril), each with intensive lifestyle counseling, and asked about sexual function by physician interview at baseline and yearly. At baseline 14.4% of men reported a sexual problem and 12.2% had trouble getting or keeping an erection; 4.9% of women reported one. Incidence of erection problems was 9.5% through 24 months and 14.7% through 48, and it tracked the drug. Chlorthalidone ran 17.1% against placebo at 8.1% through 24 months (P = .025). Doxazosin came in lowest, close enough to placebo that the paper calls it nonsignificant, and the other drug arms sat near placebo, amlodipine among them. The beta-blocker page charts it.

The reviews agree on direction and print no numbers. Manolis and colleagues (2012) say older drugs harm erection scores while nebivolol and ARBs are neutral or beneficial. La Torre and colleagues (2015) say most published studies are methodologically weak, few are randomized, most cover men, and they list ARBs as beneficial on the literature. Zhong and colleagues (2022) call beta-blockers the only class with relatively strong evidence of harming women's sexual function, and call ARBs relatively beneficial in the authors' own wording. Corona and colleagues (2025) keep beta-blockers as the class most often tied to erection problems, with nebivolol faring better. Dharmarajan and colleagues (2015) treat sexual function as one tolerability item among several, set beside diabetes and falls when a drug is chosen for an older adult. Of the ordinary things sitting beside blood pressure, sleep apnea and low libido is the one most often missed in the same household.

What has been counted, in order

Seven papers have counted desire, sexual activity or erection problems in people on blood-pressure medication, and they read best in the order they appeared. The oldest is a large randomized trial that never tested an angiotensin receptor blocker at all. The only losartan study ever run had no control group. Four of the strongest comparisons used valsartan, a sibling drug in the same class. The two newest reviews pooled everything available and found almost nothing. Every number below comes from a published abstract, with its caveat attached.

ARBs in the studies: what each measured, and whose number it is

Study	Design	Who	Finding	Whose number
Llisterri 2001	Open-label, no control	82 hypertensive men with sexual difficulties	Satisfaction 7.3% to 58.5%	Losartan's, uncontrolled
Fogari 2002	Double-blind	110 men aged 40 to 49	Valsartan 5.8 to 7.4 episodes a month, P = 0.058	Valsartan's
Fogari 2004	Randomized	120 postmenopausal women	Desire +38% on valsartan, -18% on atenolol	Valsartan's
Fogari 2001	Double-blind crossover	120 men randomized	Valsartan 8.3 to 10.2, carvedilol 8.2 to 3.7	Valsartan's, against a beta blocker
Ismail 2019	Meta-analysis	Four trials, 2,809 men	Activity up with valsartan; erection scores not significantly up with losartan or telmisartan	The class's, mixed drugs
Farmakis 2022	Network meta-analysis	25 trials, 7,784 people	No class beat placebo on erection scores	Every class's
Thomas 2016	Cross-sectional, SPRINT baseline	690 women in the quality-of-life subset	ACE inhibitor or ARB users more often sexually active, odds 1.66	A pooled class's, in women

What actually helps, graded honestly

One lever has trial evidence behind it: which class of blood-pressure medication you are on. The direction is consistent across this whole set of papers. In every head-to-head, the drug that moved downward was a beta blocker.

Fogari and colleagues (2002) put 110 men on valsartan or atenolol for 16 weeks. Activity fell from 6.0 to 4.2 intercourse episodes a month on atenolol and rose from 5.8 to 7.4 on valsartan, with testosterone down on atenolol and unchanged on valsartan. The same group's 2001 crossover ended at 10.2 episodes a month on valsartan against 3.7 on carvedilol, with erection problems reported by 15 men on carvedilol and one man on valsartan.

Changing the class is a real lever, and it belongs to your prescriber. Blood pressure comes first, and the choice turns on your heart, your kidneys, your age and the rest of your regimen. Farmakis and colleagues (2022) pooled 25 trials and 7,784 people and found no class separated from placebo on erection scores, with a high risk of bias in most of that work, so nobody can promise you a swap that settles this.

The pressure itself is the second lever, and it pulls the same way. Choy and colleagues (2019) pooled 31 studies and 18,260 women and found 42.1% of hypertensive women scoring in the dysfunction range, with odds of 2.789 against women with normal pressure (95% CI 1.452 to 5.357). Kloner and colleagues (2007) puts about 67 to 68% of men with hypertension in some degree of erection problems, a figure credited to recent analyses with no design stated. Spatz and colleagues (2013) surveyed 3,005 adults aged 57 to 85 and found sexual activity at 35.2% in women whose hypertension was found and managed against 58.0% in women without it, self-reported and cross-sectional. Good control is not the enemy here.

Sleep apnea rides with hypertension and drags wanting with it, so have that assessed. Nothing has been tested as a fix for angiotensin receptor blocker difficulties, because those trials found no difficulty to fix. For the wider picture, see low libido in men, low libido in women and exercise and libido.

Does it wear off on its own?

Three trials measured the early weeks, and they agree on one thing: the first weeks are a poor guide to the twelfth. In Fogari and colleagues (2001), men on valsartan dipped from 8.3 intercourse episodes a month to 6.6 in the first month, a change that was not significant, then climbed to 10.2 as they kept taking it, and the crossover confirmed the climb. The 1998 crossover from the same group found the same shape on lisinopril: 7.1 episodes down to 5.0 in month one, back to 7.7 by week 16, while atenolol stayed at 4.2. The losartan study ran 12 weeks and reported its improvement already inside that window, with no control group to compare it against. Nobody has followed losartan longer than 12 weeks with a sexual measure. Month one is the month to wait through, with your prescriber told what you are noticing.

What to bring to your prescriber

One appointment resolves most of this. Bring the specifics below in writing, and the conversation moves from a shrug to a plan. Your prescriber needs the sequence, more than the feeling.

1. The timeline. When the flatness started, against the day you started losartan and against the start of anything before it.
2. Which drug came before. A beta blocker leaves a mark the ARB later gets blamed for: atenolol took activity from 6.0 to 4.2 episodes a month in Fogari and colleagues (2002), and carvedilol took it from 8.2 to 3.7 in the 2001 crossover.
3. The blood pressure itself and how long it ran high. Choy and colleagues (2019) pooled odds of 2.789 (95% CI 1.452 to 5.357) in hypertensive women, and Spatz and colleagues (2013) found activity at 66.5% in men with managed hypertension against 71.5% in men without it.
4. Every other medicine in the mix, diuretics included. Grimm and colleagues (1997), the TOMHS trial of 902 people, found erection problems in 17.1% on chlorthalidone against 8.1% on placebo through 24 months.
5. Ask to be asked. In the Swedish spontaneous-report file (Ekman and colleagues, 2010), 43 of 59 antihypertensive erection-problem reports, 72%, improved when the drug stopped. Those are counts with no denominator, so read them as a signal.
6. The supplement question, bottle in hand. The label says no for anyone on blood-pressure medication, and that answer belongs to your prescriber.

The everyday levers, and where a botanical fits

Everyone reading this page is on blood-pressure medication, and that fact settles this section before anything else. NUUD's label says: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For a reader on losartan, the answer to the supplement question is no, unless the prescriber who knows your kidneys and your pressure says otherwise.

A few ordinary things move desire, and the free ones do more work than the internet admits.

• Sleep, in amount and in quality. Midnight dosing, a snoring partner and untreated sleep apnea all eat the same hours. Sleep, libido and testosterone covers that.
• Movement you can keep up. The trials here changed a pill, and a walking routine changes the vessels underneath.
• Your blood pressure, brought down and kept down, as the first lever on this list, with the class chosen around this conversation.
• Time with a partner, with nothing expected at the end.
• A botanical supplement, for a partner or a reader the label does not cover, and as the smallest lever here.

NUUD is a botanical supplement built around desire in general. It does nothing for blood pressure, for losartan, or for the side effects of any medication, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your prescriber decides the rest. If a partner who is not on blood-pressure medication wants to try it, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Two answers circulate, and both are useless. The first is the shrug: it is common, it comes with the pills, live with it. The second is the forum certainty that every blood-pressure pill kills libido and yours is on the list. The counted evidence sits between them. Across 25 randomized trials and 7,784 people, no drug class separated from placebo on erection scores. In every head-to-head in this record, the drug that moved was a beta blocker. The single losartan study, 82 men over 12 weeks, had no control group, which is why its good number cannot carry a prescription.

What flattens wanting is usually a stack: the pressure, the years it ran high before anyone named it, the medication you came off, the sleep you lost, the mood, the marriage that turned into logistics. That stack is why my numbers are fine and I still feel flat is such a common sentence here, and why nothing is wrong with you sits at the top of this page. Feeling flat says nothing about your character, and your sex life has a long way left to run. People want to want it again. People say they just want to feel normal again. Both are reasonable things to ask a prescriber for, out loud, with the numbers above in your hand.

Keep reading

• Beta blockers and sex drive
• Statins and sex drive
• Sleep apnea and low libido
• Does diabetes affect sex drive?
• Low libido in men
• Low libido in women

Frequently asked questions

Does losartan lower sex drive?
Probably not, and the honest answer is that nobody has tested it well enough to be certain. Farmakis and colleagues (2022) pooled 25 trials and 7,784 people and found no blood-pressure class separated from placebo on erection scores, angiotensin receptor blockers included, in work with a high risk of bias. The one losartan study, Llisterri and colleagues (2001) in 82 men over 12 weeks, ran the other way, with satisfaction rising from 7.3% to 58.5%, and it had no control group. The valsartan trials point upward, and valsartan is a sibling drug.

Does losartan cause erection problems?
Unlikely, on what exists. Ismail and colleagues (2019) pooled erection scores for losartan or telmisartan against control, 203 men against 232, and found no significant rise, with an interval from -0.97 to -3.69 around a positive point estimate and heterogeneity of 80%, so read that as unstable. The Swedish spontaneous-report file (Ekman and colleagues, 2010) lists 9 angiotensin receptor blocker cases among 225 erection-problem reports, counts with no denominator of users. Farmakis and colleagues (2022) found no class worse than placebo.

Is losartan better than a beta blocker for sex drive?
The comparisons that exist favor the ARB side, and every one of them used valsartan. Fogari and colleagues (2002) ran 110 men for 16 weeks: activity went from 5.8 to 7.4 intercourse episodes a month on valsartan, P = 0.058 against placebo, and from 6.0 to 4.2 on atenolol. The 2001 crossover ended at 10.2 episodes on valsartan against 3.7 on carvedilol. Fogari and colleagues (2004) found desire up 38% on valsartan and down 18% on atenolol in 120 postmenopausal women. Losartan shares that class, and the class did not beat placebo in the 25-trial pool.

Does losartan affect women's sex drive?
No losartan trial in women appears in this evidence. Choy and colleagues (2019) pooled 31 studies and 18,260 women and found 42.1% of hypertensive women scoring in the dysfunction range, with odds of 2.789 against women with normal pressure (95% CI 1.452 to 5.357), and no difference between drug classes, angiotensin receptor blockers included. Thomas and colleagues (2016), in 690 women from SPRINT, found ACE inhibitor or ARB users more often sexually active, odds 1.66 (95% CI 1.12 to 4.27), a wide interval on baseline data.

Can I take a botanical supplement with losartan?
No, not as the label is written. It says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients, and losartan is that medication. NUUD does nothing for blood pressure, nothing for losartan, and has no role in managing any medical condition. No interaction studies exist for this formula in anyone. If your prescriber reads the label and says yes, that conversation is the whole answer.

References

1. Choy CL, Sidi H, Koon CS, et al. Systematic Review and Meta-Analysis for Sexual Dysfunction in Women With Hypertension. The journal of sexual medicine. 2019;16(7):1029-1048. https://pubmed.ncbi.nlm.nih.gov/31113742/
2. Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Current hypertension reports. 2012;14(4):285-92. https://pubmed.ncbi.nlm.nih.gov/22581395/
3. Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovascular drugs and therapy. 2022;36(5):903-914. https://pubmed.ncbi.nlm.nih.gov/33945044/
4. Patel JP, Lee EH, Mena-Hurtado CI, Walker CN. Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. Current cardiology reports. 2017;19(9):89. https://pubmed.ncbi.nlm.nih.gov/28836189/
5. Ismail SB, Noor NM, Hussain NHN, Sulaiman Z, Shamsudin MA, Irfan M. Angiotensin Receptor Blockers for Erectile Dysfunction in Hypertensive Men: A Brief Meta-Analysis of Randomized Control Trials. American journal of men's health. 2019;13(6):1557988319892735. https://pubmed.ncbi.nlm.nih.gov/31795911/
6. La Torre A, Giupponi G, Duffy D, Conca A, Catanzariti D. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48(1):1-6. https://pubmed.ncbi.nlm.nih.gov/25405774/
7. Spatz ES, Canavan ME, Desai MM, Krumholz HM, Lindau ST. Sexual activity and function among middle-aged and older men and women with hypertension. Journal of hypertension. 2013;31(6):1096-105. https://pubmed.ncbi.nlm.nih.gov/23640604/
8. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. The American journal of the medical sciences. 2001;321(5):336-41. https://pubmed.ncbi.nlm.nih.gov/11370797/
9. Thomas HN, Evans GW, Berlowitz DR, et al. Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT). Journal of hypertension. 2016;34(6):1224-31. https://pubmed.ncbi.nlm.nih.gov/27032074/
10. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. American journal of hypertension. 2004;17(1):77-81. https://pubmed.ncbi.nlm.nih.gov/14700518/
11. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension (Dallas, Tex. : 1979). 1997;29(1 Pt 1):8-14. https://pubmed.ncbi.nlm.nih.gov/9039073/
12. Ekman E, Hägg S, Sundström A, Werkström V. Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers. Drug, healthcare and patient safety. 2010;2:21-5. https://pubmed.ncbi.nlm.nih.gov/21701615/
13. Fogari R, Preti P, Derosa G, et al. Effect of valsartan and atenolol on sexual activity and plasma testosterone in hypertensive men. European journal of clinical pharmacology. 2002;58(3):177-80. https://pubmed.ncbi.nlm.nih.gov/12107602/
14. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. American journal of hypertension. 2001;14(1):27-31. https://pubmed.ncbi.nlm.nih.gov/11206674/
15. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. American journal of hypertension. 1998;11(10):1244-7. https://pubmed.ncbi.nlm.nih.gov/9799042/
16. Zhong Q, Anderson Y. Management of Hypertension with Female Sexual Dysfunction. Medicina (Kaunas, Lithuania). 2022;58(5):. https://pubmed.ncbi.nlm.nih.gov/35630054/
17. Kloner R. Erectile dysfunction and hypertension. International journal of impotence research. 2007;19(3):296-302. https://pubmed.ncbi.nlm.nih.gov/17151696/
18. Corona G, Vena W, Pizzocaro A, et al. Anti-hypertensive medications and erectile dysfunction: focus on β-blockers. Endocrine. 2025;87(1):11-26. https://pubmed.ncbi.nlm.nih.gov/39269577/
19. Wang M, Chen J, Qi M, et al. Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial. Journal of clinical hypertension (Greenwich, Conn.). 2025;27(9):e70145. https://pubmed.ncbi.nlm.nih.gov/40965515/
20. Dharmarajan TS, Dharmarajan L. Tolerability of Antihypertensive Medications in Older Adults. Drugs & aging. 2015;32(10):773-96. https://pubmed.ncbi.nlm.nih.gov/26442857/

This article is for general education and is not medical advice. High blood pressure is a medical condition that only a licensed clinician can diagnose and manage, and losartan is a prescription medicine that should only be changed with your prescriber. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing high blood pressure, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.